Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Having the VV family resign from the BOD is a good thing to happen.
just like Sessions is about to resign from AG...
the facts get twisted here daily...TRTC
agreed, sometimes it takes guts to dollar cost average down on a stock that went from .30 to .15 . Smart cookies should just dollar cost average down and take the cheap price as a gift. Always keep some dry powder ready.
Recreational NV and the CA in 2018 will be the key to drive this stock higher.
doubt that mags... I'm guessing most here are averaged in the .30's...so that would be back to even.And if they are smart they would buy atb .17 to dollar cost average down...... I'm in at .195 and will double my money easy here by late summer for sure. GLTA
TRTC
"For valuation purposes, we have constructed a probability adjusted discounted cash flow model that takes into account potential revenues from VK5211 in hip fracture, VK2809 in NASH, and VK0214 in ALD.
We model for peak revenues for VK5211 of approximately $600 million in the U.S. and $1 billion in the E.U. based on compelling preclinical and early clinical data. We look forward to analyzing the data from the ongoing Phase 2 study of VK5211 for the treatment of hip fracture in late summer 2017.
"We estimate potential peak worldwide revenues for VK2809 of $2.5 billion based upon the low level of adverse events seen with the drug in early clinical testing along with data that is just as good if not better than current treatment options for dyslipidemia. We anticipate topline results from the recently initiated Phase 2 study of VK2809 in hypercholesterolemia and fatty liver disease in the fourth quarter 2017.
For ALD, since it is an orphan indication we believe the drug would likely command premium pricing, thus we model for a yearly cost of $150,000 in the U.S. and $120,000 in Europe, leading to estimated peak worldwide sales of approximately $450 million.
Based on these numbers, and using an 18% discount rate, we arrive at a valuation of $8/share. We continue to believe that Viking’s shares are significantly undervalued. This is particularly evident on a comparative basis with Madrigal Pharmaceuticals, Inc. (MDGL), which is developing a TRß agonist that is also in Phase 2 testing for the treatment of fatty liver disease. We believe Viking’s TRß agonists have potentially superior efficacy and fail to see why Viking is trading at approximately 1/6th the valuation of Madrigal. Small-cap biotech investors should take a serious look at Viking ahead of data readouts later in 2017."
5 U.S. Cannabis Stocks on Track for >$10mm Annual Revenue
https://www.newcannabisventures.com/5-u-s-cannabis-stocks-on-track-for-10mm-annual-revenue/
It hit 1.52 ++ in pre market today so look for it get there this week.glta
It could ""spark " a whole new rally...Pun intended :] .
Retail will be chasing it soon, while Ligand and crew / 72% of float insiders holding it.... flock of Seagulls will drive it up.
VKTX
"We are excited about the initial results from this study, as they demonstrate promising effects in a model of NASH that we believe reflects many characteristics of the disease in humans," said Brian Lian, Ph.D., chief executive officer of Viking. "The robust effect across multiple disease metrics, including reductions in collagen and lipotoxic lipids suggests potential benefits on endpoints important in NASH. The observed reductions in hepatic collagen content and fibrosis, by morphometric analysis, are particularly noteworthy, as these data represent the first quantitative histologic evidence that treatment with a thyromimetic agent can potentially improve NASH-related fibrosis. These results provide further support for the development of VK2809 in these settings."
not unless TRTC works a new lease agreement when New jersey legalizes...otherwise sell EG.
Green day tomorrow too. Calling .19
TRTC
TRTC will be profitable for sure by 2018 Q2.
Unless you have bought from both first hand , Smart MJ users would know that those numbers are incorrect.
300.00 oz. is top shelf
100.00 oz. is dirt weed on the street.
TRTC
I know both markets well,.. and The truth is 300 an Oz. is Top shelf bud.
Any Oz. on street or dispensary that is 100.00 is rubble shwag weed.
TRTC
Nice green spike at the end of trading. ...Resign Sessions you dirty bird.
Flock of dirty Seagulls retail lol ..fly VKTX , flap your wings....$$$$$$
"expect a hearing on the matter to be scheduled for some time in the next couple of weeks,” Klapstein said in an email to The Associated Press. “We are still looking toward a July 1 launch of the program.”
incorrect, July 1 is still on.
July 1 is still on.
TRTC
Review Identifies 140 Controlled Clinical Trials Related to Cannabis
http://blog.norml.org/2017/06/04/review-identifies-140-controlled-clinical-trials-related-to-cannabis/
Veterans with PTSD deserve access to medical marijuana (Commentary)
http://www.syracuse.com/opinion/index.ssf/2017/06/veterans_with_ptsd_deserve_access_to_medical_marijuana_commentary.html
simple explanation TRTC is seed to sale, the other one is not. TRTC has 20X more Assets as well. Also do not forget about the 5 acre greenhouse in NJ down the line. last post today ..enjoy the weekend.
TRTC is better positioned for much more revenue than that other stock can only dream of doing.
TRTC 2018 $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
Recreational revenue. 2018 will be profitable , you are underestimating.The revenue will be much more than expenses by when the Buildout is complete in Q1 2018
I agree, but still think they want to see if they can build a Greenhouse in Nevada first and are waiting for regulators to make it happen.
TRTC will be a profitable company in 2018.
CA revenue will be bigger than all the other legal MJ states combined.
TRTC
"Is anything big going to happen this year? Las Vegas / July
TRTC
"The existence of specific receptors in mammalian cells that recognize a plant-derived substance rekindled the question raised two decades earlier, after brain receptors for morphine had been first described, i.e., is there an endogenous ligand? A positive answer was provided in 1992 by the report by Devane et al. describing the isolation from porcine brain of the lipid arachidonoyl ethanolamide, named anandamide, which bound to the brain cannabinoid receptor with reasonably high affinity and mimicked the behavioral actions of THC when injected into rodents (Devane et al., 1992). Three years later a second endocannabinoid, 2-arachidonoylglycerol (2-AG), was discovered independently by Mechoulam et al. (1995) and Sugiura et al. (1995). Since then, a number of related endogenous lipids with endocannabinoid-like activity have been reported (Fig. 1c), but follow-up studies about biosynthesis, cellular transport, metabolism, and biological function have focused on anandamide and 2-AG, with much less information available about the other compounds with endocannabinoid-like properties. The biochemical aspects of endocannabinoids have been recently reviewed by Bisogno et al. (2005)."
SGBY sliding down another 7% today , all the dilution, going sub penny soon.
All Cannabis is Medical IMO, anytime you smoke or ingest it you are helping regulate the Endocannabinoid system....everybody has the receptors for it, Our Bodies were designed for cannabis.
TRTC
"but Americans are burning through even more weed, and we'd wager that's going to go up, too."
I suspect many newbies will be trying weed for the first time in Vegas.
I hear they are looking for something in So Cal. would prefer they come here to San Diego,
Compared to other Biotech stocks VKTX is extremely undervalued. Looking forward to Q3 and Q4 when this stock at least triples in Value after Great results in both Phase 2 trials.
better than Ice cream https://mjbizdaily.com/chart-retail-marijuana-sales-vs-industries-goods/
VKTX target price 7.50 https://stockflare.com/stock/VKTX.O
relax, it was not for insiders, and Pool party's are Popular in Vegas and Blum "the Brand" should do it more often. :]
TRTC/ Blum Pool Party https://www.facebook.com/terratechcorp/posts/1523896807661626
SAN DIEGO, May 31, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver corporate presentations at two upcoming investor conferences. Dr. Lian will present at the 7th Annual LD Micro Invitational, being held June 6-7, 2017 in Los Angeles and the 2017 Marcum Microcap Conference, being held June 15-16, 2017 in New York City.
Details of these presentations are as follows:
7th Annual LD Micro Invitational
Time/Date: 8:30 a.m. PT on Tuesday, June 6, 2017
Location: Luxe Sunset Boulevard Hotel, Los Angeles
Room: Track 1
2017 Marcum Microcap Conference
Time/Date: 3:00 p.m. ET on Thursday, June 15, 2017
Location: Grand Hyatt Hotel, New York
Room: Broadway – Conference Level